Futuremeds S.R.L.
- Address
- Calea Bucuresti Nr. 318, 500299 Brasov, Romania
Cardiovascular Diseases
At Futuremeds S.R.L. in Brasov, clinical research in cardiovascular diseases focuses on heart failure and related kidney impairment, with studies designed to assess whether new treatment approaches can better reduce cardiovascular death and worsening heart events.
- Heart failure with impaired kidney function
- Reducing cardiovascular events and hospitalizations
- Evaluating improved treatment effectiveness
This work reflects a strong interest in finding more effective options for people with complex heart and kidney conditions.
Immune System Diseases
Research in immune system diseases at this site includes studies in atopic dermatitis, alopecia areata, and hidradenitis suppurativa, aiming to understand how new therapies may help patients who have not responded well to current care.
- Atopic dermatitis
- Alopecia areata
- Moderate-to-severe hidradenitis suppurativa
These trials are mainly focused on testing potential treatments that could improve symptom control and overall quality of life in chronic inflammatory skin conditions.
Skin and Connective Tissue Diseases
The dermatology-focused program at Futuremeds S.R.L. also covers skin and connective tissue diseases, with studies looking at difficult-to-treat conditions that affect the skin, hair, and surrounding tissues. The goal is to evaluate new therapies for better disease control and patient outcomes.
- Atopic dermatitis
- Alopecia areata
- Hidradenitis suppurativa
These trials support ongoing efforts to improve treatment options for chronic dermatologic disorders that can strongly affect daily life.
Nutritional and Metabolic Diseases
Clinical trials in nutritional and metabolic diseases at this pharmaceutical company site examine obesity and cancer-associated cachexia, with the purpose of identifying therapies that may help manage body weight and muscle loss more effectively.
- Obesity
- Cancer-associated cachexia
- Improving weight and nutritional outcomes
By studying these conditions, the site contributes to research on treatments that may support healthier metabolism and better physical resilience.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
- 1AstraZeneca AB2active
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AstraZeneca AB2trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 442 other sites in Romania
Therapeutic Area Benchmark — Romania
Select a therapeutic area to compare against other sites in Romania.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Romania
Market Share
Country: Romania
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Futuremeds S.R.L.
lock Showing 1 of 3 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3b/4 Randomized, Open-label, Efficacy Assessor-Blinded Study, to Evaluate the Efficacy and Safety of Upadacitinib for the Treatment of Adult Subjects with Moderate to Severe Atopic Dermatitis and Inadequate Response to Dupilumab (SWITCH-UP) | AbbVie Deutschland GmbH & Co. KG | Phase I | Recruiting | Mar 2026 | — |
IMP list
lock Showing 1 of 5 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Dapagliflozin | 2 | Unknown | 2024-07-12 | 2024-07-12 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.